Effect of perioperative targeted therapy duration on prognosis in patients with gastrointestinal stromal tumors undergoing neoadjuvant imatinib therapy: A nationwide retrospective study
European Journal of Surgical Oncology · 2026-09 · 52 (9) · 111981
DOI: 10.1016/j.ejso.2026.111981 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2026-09. Verfasst von Hongkun Tian und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Imatinib Mesylate, Gastrointestinal Stromal Tumors, Neoadjuvant Therapy, Antineoplastic Agents. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Contemporary evidence highlights a paucity of systematic research addressing the prognostic implications of total targeted therapy duration in the neoadjuvant setting. Parallel to this, the optimal timeframe for preoperative therapy remains a subject of unresolved debate in clinical practice. In this study, we estimated the impact of total targeted therapy duration on prognosis in patients with gastrointestinal stromal tumors (GIST) undergoing neoadjuvant imatinib therapy. METHODS: In this nationwide study, we retrospectively analyzed the clinical data from 186 GIST patients receiving neoadjuvant imatinib therapy from January 2010 to December 2021. Clinical data including baseline characteristics, treatment pattern, treatment outcome, adverse events and survival status were collected. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and safety. Cox regression analysis was used to analyze the prognostic factors of PFS and OS. RESULTS: Among 186 patients, 149 (80.1%) were aged ≤65 years and 110 (59.1%) were male. Regarding neoadjuvant imatinib treatment duration, 59 patients (31.7%) had less than 6 months, 97 (52.2%) patients had 6 to 12 months, and 30 (16.1%) patients had more than 12 months. Multivariate Cox regression analysis indicated that residual mitotic index (>5/50 HPF: HR = 5.80, 95% CI: 2.56-13.15, P 5/50 HPF: HR = 4.40, 95% CI: 1.29-15.06, P = 0.018), multivisceral resection (HR = 4.07, 95% CI: 1.09-15.19, P = 0.037), and adjuvant imatinib therapy (HR = 0.04, 95% CI: 0.01-0.17, P < 0.001) were independent prognostic factors for OS. Maximally selected log-rank analysis identified 35 months and 45 months as the optimal cut-offs for adjuvant and total targeted therapy durations, respectively. No significant difference was found in PFS and OS among patients with different neoadjuvant imatinib therapy durations (P = 0.233, P = 0.326). CONCLUSIONS: Prolonged adjuvant and total targeted therapy durations correlate with improved survival in GIST patients receiving neoadjuvant imatinib, whereas neoadjuvant imatinib duration alone does not independently affect long-term outcomes. Additionally, a low residual mitotic index remains a robust histopathological predictor of favorable prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Gastrointestinal Surgery, Peking University People's Hospital, Peking University, Beijing, China.
- Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University, Qingdao, China.
Zitieren
APA
Tian, H., Gao, X., Zhang, J., Fu, Y., Gao, Z., Zhou, Y., Qiu, H., Tao, K., Zhao, X., Fu, Y., Zhang, B., Tang, J., Wang, M., Zhang, X., & Zhang, P. (2026). Effect of perioperative targeted therapy duration on prognosis in patients with gastrointestinal stromal tumors undergoing neoadjuvant imatinib therapy: A nationwide retrospective study. European Journal of Surgical Oncology, 52(9), 111981. https://doi.org/10.1016/j.ejso.2026.111981
Vancouver
Tian H, Gao X, Zhang J, Fu Y, Gao Z, Zhou Y, et al. Effect of perioperative targeted therapy duration on prognosis in patients with gastrointestinal stromal tumors undergoing neoadjuvant imatinib therapy: A nationwide retrospective study. European Journal of Surgical Oncology. 2026;52(9):111981. doi:10.1016/j.ejso.2026.111981
BibTeX
@article{Tian2026,
author = {Tian, Hongkun and Gao, Xiaodong and Zhang, Jun and Fu, Yang and Gao, Zhidong and Zhou, Yanbing and Qiu, Haibo and Tao, Kaixiong and Zhao, Xuefeng and Fu, Yingfeng and Zhang, Bo and Tang, Jianjun and Wang, Ming and Zhang, Xinhua and Zhang, Peng},
title = {Effect of perioperative targeted therapy duration on prognosis in patients with gastrointestinal stromal tumors undergoing neoadjuvant imatinib therapy: A nationwide retrospective study},
journal = {European Journal of Surgical Oncology},
year = {2026},
volume = {52},
number = {9},
pages = {111981},
doi = {10.1016/j.ejso.2026.111981}
}
EUVIMED